reason report
log reduct fall wood move
stock pt
bottom line report earn initi
registr studi dcr-phxc initi
open label studi dose first hbv patient
dcr-hbv expect set sever meaning data
readout program back half year otherwis
routin report manag comment potenti bar success
hbv spark controversi around data signal manag
seen thu far program see misinterpret
street hbv patient dose yet make imposs
manag seen data antigen knockdown model
adjust account higher expect opex lower
pt reiter outperform rate share
financi glanc revenu recogn
collabor agreement op boehring
ingelheim bi compar estim report
 expens estim
sg expens higher project
quarter march compani held cash
cash equival held-to-matur invest manag
expect financ compani current oper plan beyond
meaning data readout ph hbv program expect
screen registr studi
on-going patient dose expect initi align
fda regard approv endpoint patient
reach full approv discuss regard appropri
primari endpoint patient on-going healthi volunt
dose phase studi dcr-hbv first patient
chronic hbv expect dose proof-of-concept data
program plan discuss hbv program
call shift bar success whether achiev
antigen reduct less two half log expect set
competitor data commentari enough attract partner
advanc dcr-hbv program note specul
manag comment potenti hbv data like unwarr
hbv patient yet dose studi
year price history/av daili volume mil
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform lead candid dcr-phxc rnai therapeut
target ldha treatment subtyp primari hyperoxaluria ph vs competitor
alni lumasiran treat ph type see dcr-phxc potenti establish
new standard care ph type split market ph type
regulatori path approv urinari oxal reduct materi de-risk alni
fda feedback lumasiran program expect start pivot trial ph type
patient readout repres materi de-risk event success
outcom transform commerci rare diseas compani attract duopoli
market best-in-class breadth label ascrib valu drna pipelin beyond ph
take asset increment option upsid
price target base dcf methodolog forecast risk-
adjust sale dcr-pxhc ascrib explicit valu pipelin asset
explicitli model expens result cash flow assum discount rate
consist clinical-stag pre-revenu compani coverag univers
termin growth rate addit
includ drna net cash balanc valuat
risk view outlook valuat dicerna includ major chang price
reimburs coverag unit state europ rare diseas drug dcr-
phxc revenu forecast dcr-phxc subject risk better-than-expect market
share lumasiran unmodel competit entrant use disrupt technolog
gene edit risk includ clinic regulatori disappoint dcr-phxc excess
factor probabl adjust program addit dcr-phxc sale
profit fail match estim dilut financ may requir order
support futur commerci oper clinic develop pipelin agent
incom statement mm
less accret dividend redeem convert
net loss attribut common stockhold
sec file svb leerink estim
bs mm
cash equival
properti equip net
accru expens current liabil
defer rent net current portion
long-term payabl accru interest
total liabil stockhold equiti
sec file svb leerink estim
flow mm
chang
chang work capit
purchase/sal invest net
proce stock option
start eq
end eq
sec file svb leerink estim
treat dcr-phxc
treat dcr-phxc
total share outstand valuat
brand
type event
event trial detail
date known
up/down
expect
initi registr studi
dose first patient non-cirrhot chronic hbv
phase
interim readout ole
svb leerink llc equiti research compani file
